.webp)
67/100B67.290
USD
-0.26
(-0.38%)
Post Trading·68.800USD+1.510(+2.24%)
Last updated: · Delayed 15 min
Fair value63.11Plus+7%48Price 67.2994
Q4 FY2026 · Earnings report
EPS estimate 1.53Revenue estimate 960.74M
Q4 FY2026 · Earnings report
EPS estimate 1.53Revenue estimate 960.74M
Royalty Pharma current ratioWhat is the current ratio? The current ratio is current assets divided by current liabilities: whether what a company will turn into cash within a year covers what it owes within a year.
Royalty Pharma's current ratio is 1.29: current assets of 1.53B USD against current liabilities of 1.18B USD due within a year.
- Today
- 1.29
- Average, 5 years
- 6.29
- Low, 5 years
- 0.97
- High, 5 years
- 21.95
Current ratio = current assets ÷ current liabilities = 1.53B ÷ 1.18B = 1.29
Current ratio
Total current assets
Total current liabilities
Current assets over current liabilities at each quarter end: above 1, what falls due within a year is covered by what turns into cash within a year.
Current ratio by year and by quarter
| Fiscal year | Period ending | Current ratio | Total current assets | Total current liabilities |
|---|---|---|---|---|
| Today | 1.29 | 1.53B | 1.18B | |
| FY2025 | 31 Dec 2025 | 0.97 | 619.00M | 636.21M |
| FY2024 | 31 Dec 2024 | 1.44 | 1.80B | 1.25B |
| FY2023 | 31 Dec 2023 | 7.90 | 1.27B | 161.38M |
| FY2022 | 31 Dec 2022 | 2.19 | 2.55B | 1.17B |
| FY2021 | 31 Dec 2021 | 16.81 | 2.88B | 171.25M |
| FY2020 | 31 Dec 2020 | 8.76 | 2.70B | 307.89M |
| FY2019 | 31 Dec 2019 | 2.50 | 832.07M | 333.42M |
| FY2018 | 31 Dec 2018 | 4.50 | 2.61B | 580.17M |
| FY2017 | 31 Dec 2017 | 7.69 | 2.95B | 383.41M |
| FY2016 | 31 Dec 2016 | 10.10 | 3.00B | 297.32M |
| FY2015 | 31 Dec 2015 | 9.68 | 3.04B | 314.39M |
| Quarter | Period ending | Current ratio | Total current assets | Total current liabilities |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | 1.29 | 1.53B | 1.18B |
| Q2 FY2026 | 30 Jun 2026 | 1.29 | 812.00M | 630.93M |
| Q1 FY2026 | 31 Mar 2026 | 2.66 | 1.43B | 535.68M |
| Q4 FY2025 | 31 Dec 2025 | 0.97 | 619.00M | 636.21M |
| Q3 FY2025 | 30 Sept 2025 | 3.48 | 1.85B | 530.80M |
| Q2 FY2025 | 30 Jun 2025 | 1.26 | 1.52B | 1.21B |
| Q1 FY2025 | 31 Mar 2025 | 1.56 | 1.84B | 1.18B |
| Q4 FY2024 | 31 Dec 2024 | 1.44 | 1.80B | 1.25B |
| Q3 FY2024 | 30 Sept 2024 | 1.54 | 1.79B | 1.17B |
| Q2 FY2024 | 30 Jun 2024 | 9.35 | 2.58B | 275.70M |
| Q1 FY2024 | 31 Mar 2024 | 12.52 | 1.56B | 124.57M |
| Q4 FY2023 | 31 Dec 2023 | 7.90 | 1.27B | 161.38M |
| Q3 FY2023 | 30 Sept 2023 | 13.51 | 1.73B | 127.93M |
| Q2 FY2023 | 30 Jun 2023 | 2.52 | 2.95B | 1.17B |
| Q1 FY2023 | 31 Mar 2023 | 2.36 | 2.63B | 1.12B |
| Q4 FY2022 | 31 Dec 2022 | 2.19 | 2.55B | 1.17B |
| Q3 FY2022 | 30 Sept 2022 | 2.07 | 2.34B | 1.13B |
| Q2 FY2022 | 30 Jun 2022 | 19.22 | 3.50B | 182.33M |
| Q1 FY2022 | 31 Mar 2022 | 21.95 | 2.98B | 135.87M |
| Q4 FY2021 | 31 Dec 2021 | 16.81 | 2.88B | 171.25M |
| Q3 FY2021 | 30 Sept 2021 | 10.88 | 2.78B | 255.06M |
| Q2 FY2021 | 30 Jun 2021 | 9.53 | 2.71B | 283.99M |
| Q1 FY2021 | 31 Mar 2021 | 9.44 | 2.42B | 255.98M |
| Q4 FY2020 | 31 Dec 2020 | 8.76 | 2.70B | 307.89M |
| Q3 FY2020 | 30 Sept 2020 | 10.31 | 2.78B | 269.98M |
| Q2 FY2020 | 30 Jun 2020 | 7.52 | 3.39B | 450.97M |
| Q1 FY2020 | 31 Mar 2020 | 4.00 | 1.74B | 433.96M |
| Q4 FY2019 | 31 Dec 2019 | 2.50 | 832.07M | 333.42M |
| Q3 FY2019 | 30 Sept 2019 | — | — | — |
| Q2 FY2019 | 30 Jun 2019 | — | — | — |
| Q1 FY2019 | 31 Mar 2019 | — | 1.94B | 0.00 |
Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters.
See also:P/E ratio,Market cap,P/S ratio,Dividend yield,Debt to equity,All ratios
Common questions about Royalty Pharma's current ratio
Source: Financial Modeling Prep